Similarly, recent reports have demonstrated the association of YAP/TAZ overexpression and poor prognosis in non-small cell lung cancer (NSCLC) [60,61], colorectal [62,63], gastric [64,65], esophageal [66], breast [67], liver [68], urothelial [69], and endometrial cancer [70,71]. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.